BioChem Solutions

BioChem Solutions Inc. was a biopharmaceutical company primarily focused on the development of novel therapeutic agents for infectious and inflammatory diseases. The company's lead clinical programs included Alphamir for the treatment of HIV/AIDS and Arthromir for rheumatoid arthritis, both of which advanced into Phase 3 clinical trials. These programs were largely conducted in collaboration with the Kenya Medical Research Institute (KEMRI) and utilized trioxolane-based technology. Despite reaching late-stage development, the company faced significant regulatory and financial hurdles, leading to the discontinuation of its clinical pipeline and its eventual transition to an inactive status.